Mobic and Olmetec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mobic (meloxicam) and Olmetec (olmesartan medoxomil). Common drug interactions include diarrhoea among females and abdominal distension among males.

The phase IV clinical study analyzes what interactions people have when they take Mobic and Olmetec. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Mobic?

Mobic has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 26,684 Mobic users. Check the latest studies of Mobic.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.



On Jul, 27, 2026

40 people who take Mobic and Olmetec together, and have interactions are studied.

Mobic and Olmetec drug interactions.

What are the common drug interactions of Mobic and Olmetec, by gender? *:

female:

  1. Diarrhoea
  2. Dizziness
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Dehydration (dryness resulting from the removal of water)
  5. Ingrowing nail
  6. Renal impairment (severely reduced kidney function)
  7. Arthralgia (joint pain)
  8. Arthropod sting (arthropod bite)
  9. Chest pain
  10. Muscle spasms (muscle contraction)

male:

  1. Abdominal distension
  2. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  3. Gastric ulcer (stomach ulcer)
  4. Myocardial ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased)
  5. Pemphigoid (tense blisters on the skin)
  6. Renal impairment (severely reduced kidney function)
  7. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  8. Multi-organ failure (multisystem organ failure)
  9. Decreased appetite
  10. Dizziness

What are the common drug interactions of Mobic and Olmetec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Abdominal distension
  2. Decreased appetite
  3. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  4. Extradural abscess (pus may gather between a patient's skull and his dura)
  5. Insomnia (sleeplessness)
  6. Irritability
  7. Obsessive-compulsive disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;)
  8. Pyrexia (fever)
  9. Vomiting

10-19:

n/a

20-29:

n/a

30-39:

  1. Abdominal distension
  2. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  3. Extradural abscess (pus may gather between a patient's skull and his dura)
  4. Herpes zoster
  5. Pyrexia (fever)
  6. Vomiting

40-49:

  1. Pemphigoid (tense blisters on the skin)
  2. Renal impairment (severely reduced kidney function)
  3. Dizziness
  4. Gastric ulcer haemorrhage (bleeding ulcer of stomach)
  5. Headache (pain in head)
  6. Hepatic steatosis (fatty liver disease)
  7. Hiatus hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm)
  8. Ill-defined disorder
  9. Pneumonia
  10. Procedural pain

50-59:

n/a

60+:

  1. Diarrhoea
  2. Dizziness
  3. Hypoproteinaemia (too little prolactin circulating in the blood)
  4. Muscle spasms (muscle contraction)
  5. Osteonecrosis of jaw (death of bone of jaw)
  6. Seborrhoeic dermatitis (a common, inflammatory skin condition that causes flaky, white to yellowish scales to form on oily areas such as the scalp)
  7. Abasia (inability to walk)
  8. Anal fissure
  9. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  10. Gastric ulcer (stomach ulcer)

What are the existing conditions these people have? *

  1. Constipation: 9 people, 22.50%
  2. Diabetes: 7 people, 17.50%
  3. Gastritis (inflammation of stomach): 6 people, 15.00%
  4. Back Pain: 5 people, 12.50%
  5. Type 2 Diabetes: 4 people, 10.00%
  6. Metastases To Bone (cancer spreads to bone): 4 people, 10.00%
  7. Breast Cancer: 4 people, 10.00%
  8. Cancer Pain: 4 people, 10.00%
  9. Pain: 4 people, 10.00%
  10. Osteoporosis (bones weak and more likely to break): 4 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mobic and Olmetec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mobic and Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mobic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mobic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Olmetec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on meloxicam and olmesartan medoxomil (the active ingredients of Mobic and Olmetec, respectively), and Mobic and Olmetec (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: